Sandoz Delivers Denosumab Data As Biogen Sues On Tysabri

Company Eyeing 2024 Denosumab Launch; Natalizumab Accepted In US, EU

 
• By Dean Rudge
  
race car
Sandoz is said to be leading the race on denosumab • Source: Shutterstock

More from Biosimilars

More from Products